IL17A and hepatocellular carcinoma: The IL-17 signaling pathway, mediated by the cytokine IL-17A and its receptor IL-17 receptor A, promotes inflammation, fibrosis, and HCC progression in alcohol-related liver disease (ALD) and NASH [51].